[11C]2-(2-(Dimethylaminomethyl)phenylthio)-5-fluoromethylphenylamine

[11C]AFM

The MICAD Research Team.

Image

Table

In vitro Rodents

Background

[PubMed]

The neurotransmitter serotonin (5-HT) plays a major role in a variety of brain functions such as appetite, sleep, and mood. Neuropsychiatric disorders, including major depression, schizophrenia, and Alzheimer’s and Parkinson’s diseases (1-3), involve a dysfunction of the brain’s serotonin system. The serotonergic neurons – present in wide areas of the brain, including the hypothalamus, thalamus, and cerebral cortex – bear a protein called “serotonin transporter” (SERT) (4).

The SERT, located on the cell bodies and terminals of 5-HT neurons, is a specific marker for the number and integrity of presynaptic terminals of serotonin-producing neurons. It regulates neurotransmission by removing released serotonin from the extracellular space back into the presynaptic neuron. Commonly prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs), and their effects are obtained through interaction with (and inhibition of) the SERT (5). For that reason, in vivo imaging of the regional brain distribution of the SERT is an important tool to study the 5-HT system and the treatment of neuropsychiatric disorders.

A variety of in vivo radioligands for positron emission tomography (PET) have been evaluated for imaging the SERT. [11C]McN5652 was the first successful and widely used agent (6, 7). However, it does have some limitations; for example, its kinetics in the brain are slow and its binding ratios in humans show low or nonspecificity. It is adequate for regions with high SERT density but often provides insufficient signal-to-noise differentials for imaging brain regions with intermediate to low SERT densities (e.g., limbic and neocortical regions) because of its high nonspecific binding.

Over recent years, new PET radioligands have been synthesized and evaluated as SERT imaging agents and alternatives to [11C]McN5652. Among them, 11C-labeled N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine ([11C]DASB), 2-(2-(dimethylaminomethyl)phenylthio)-5-fluoromethylphenylamine ([11C]AFM), 5-bromo-2-[2-(dimethylaminomethylphenylthio)]phenylamine ([11C]DAPA), 2-[2-(dimethylaminomethylphenylthio)]-5-iodophenylamine ([11C]ADAM), and N,N-dimethyl-2-(2´-amino-4´-hydroxymethylphenylthio)benzylamine ([11C]HOMADAM) (8) are based on a diaryl sulfide motif (4). [11C]AFM has shown high binding affinity and good selectivity for the SERT, and displays signal/noise ratios that may enable more reliable mapping of brain regions with a low density of SERT.

Synthesis

[PubMed]

AFM and its C-11 radiolabeling precursor can be prepared in a five-step procedure, as described by Huang et al. (9). Briefly, 4-chloro-3-nitrobenzyl acetate is coupled with thiosalicylic acid to give 2-(4-acetyloxymethyl-2-nitrophenylthio)benzoic acid, which is then converted to 2-(4-acetyloxymethyl-2-nitrophenylthio)-N,N-dimethylbenzamide. Reduction of the amide functionality to the tertiary amine and cleavage of the acetyl group with borane/tetrahydrofuran complex produce 2-(4-hydroxymethyl-2-nitrophenylthio)-N,N-dimethylbenzylamine. Fluorination of this compound with bis(2-methoxyethyl)aminosulfur trifluoride is then performed to produce the benzyl fluoride 2-(4-fluoromethyl-2-nitrophenylthio)-N,N-dimethylbenzylamine. Finally, reduction of the nitro group produces AFM.

Starting with 2-(4-acetyloxymethyl-2-nitrophenylthio)benzoic acid and replacing N,N-dimethylamine hydrochloride with N-methylamine hydrochloride (in the amide formation step) leads to the formation of the C-11 labeling precursor 5-fluoromethyl-2-(2-methylaminomethylphenylthio)phenylamine. [11C]AFM is prepared from this precursor by reaction with [11C]iodomethane (in dimethyl formamide, at 80-85 °C).

The chemical and radiochemical purities of [11C]AFM produced by this method are ≥97% (as determined by high-performance liquid chromatography). The radiochemical yield at the end of the synthesis is 12.3 ± 8.1% (decay-corrected, based on [11C]iodomethane; n = 14). The specific activity of the radiotracer produced is 64,121 ± 15,836 GBq/mmol (1,733 ± 428 Ci/mmol). The total synthesis time, as reported by Huang et al. (9), is about 30-37 min.

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

Huang et al. (9) assayed the affinity of AFM for the SERT, norepinephrine transporter (NET), and dopamine transporter (DAT), using cloned human receptors expressed on HEK-293 cells and the radioligands [3H]paroxetine (for SERT), [3H]nisoxetine (for NET), and [3H]GBR12935 (for DAT). Experiments were performed according to previously published procedures (10, 11). Results showed that AFM had a high affinity and a good selectivity for SERT over NET and DAT. The authors reported the following inhibition coefficients (Kis): 1.04 ± 0.13, 663.8 ± 79.5, and >10,000 nM for SERT, NET, and DAT, respectively.

In comparative studies between various SERT radiotracers, Huang et al. (12) found no significant difference between the Kis of McN5652, ADAM, DASB, and AFM. Temperature had no significant effect on the inhibition coefficients for AFM, McN5652, and ADAM, but significantly decreased the affinity of DASB for SERT.

Animal Studies

Rodents

[PubMed]

Biodistribution studies in Sprague-Dawley rats were performed by Huang et al. (9). The experimental procedure involved injecting 3.7 MBq (100 µCi) of [11C]AFM per animal (via the tail vein) and measuring the uptake of the radiotracer at 10, 30, and 60 min post injection, after sacrifice.

Results showed rapid uptake of [11C]AFM into the brain, with accumulation in regions rich in SERTs, such as the thalamus, hypothalamus, and cortex. The reported total brain uptakes of [11C]AFM at 10, 30, and 60 min post injection were 0.70, 1.06, and 1.00% of injected dose (ID)/g of tissue, respectively. The thalamus/cerebellum and hypothalamus/cerebellum activity ratios were 6.06 ± 0.17 and 6.05 ± 1.01, respectively, at 60 min post injection. When pretreated with either cold AFM (2mg/kg of tissue) or citalopram (a SSRI), the brain uptake was significantly reduced.

Other Non-Primate Mammals

[PubMed]

No publication is currently available.

Non-Human Primates

[PubMed]

PET brain imaging studies of three adult male baboons were performed by Huang et al. (9), for time periods ranging from 0 to 90 min after administration of [11C]AFM. Results showed rapid distribution of the radiotracer in the brain, consistent with the regional concentrations of SERT. High uptakes were observed in the midbrain and thalamus, moderate uptakes were seen in the hippocampus and striatum, and low levels of radioactivity were detected in the cortical regions.

In all brain regions, the measured activity reached a peak followed by a substantial wash-out (e.g., maximum activity obtained at 41 ± 12 min with a wash-out of 21 ± 14% for the hippocampus). At 45 min post injection, the measured total brain uptake was 0.015 ± 0.001% ID/g of tissue, a result consistent with values obtained in rats. The reported thalamus/cerebellum, striatum/cerebellum, and hippocampus/cerebellum activity ratios were 3.3 ± 0.4, 2.4 ± 0.4, and 1.7 ± 0.3, respectively, at 90 min post injection. Significant differences in clearance were observed between the several baboons used in the study.

When the baboons were pretreated with citalopram (a SSRI; 4 and 6 mg/kg of tissue) 10 min before injection of [11C]AFM, a significant reduction in the brain distribution volumes was observed (30.8 ± 6.4 mL/g reduced to 15.2 mL/g (baboon A) and 29.4 ± 3.2 mL/g reduced to 21.3 mL/g (baboon B), under control conditions).

In comparative studies between the SERT radiotracers [11C]ADAM, [11C]AFM, [11C]DASB, [11C]DAPA, and [11C]McN5652, Huang et al. (12) showed that the regional-specific-to-nonspecific equilibrium partition coefficient was the highest for [11C]AFM, followed by [11C]DASB, [11C]DAPA, [11C]ADAM, and [11C]McN5652. [11C]AFM was shown to provide higher signal/noise ratios, which might enable more reliable measurement of SERT availability in regions of low SERT density.

Human Studies

[PubMed]

No publication is currently available.

References

1.
Owens MJ, Nemeroff CB. The serotonin transporter and depression Depress Anxiety 1998. 8Suppl 15–12. [PubMed: 9809208]
2.
Palmer AM, Francis PT, Benton JS, Sims NR, Mann DM, Neary D, Snowden JS, Bowen DM. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem. 1987;48(1):8–15. [PubMed: 2432177]
3.
Roth BL, Xia Z. Molecular and cellular mechanisms for the polarized sorting of serotonin receptors: relevance for genesis and treatment of psychosis. Crit Rev Neurobiol. 2004;16(4):229–236. [PubMed: 15862107]
4.
Laakso A, Hietala J. PET studies of brain monoamine transporters. Curr Pharm Des. 2000;6(16):1611–1623. [PubMed: 10974156]
5.
White KJ, Walline CC, Barker EL. Serotonin transporters: implications for antidepressant drug development. Aaps J. 2005;7(2):E421–E433. [PMC free article: PMC2750979] [PubMed: 16353921]
6.
Ichimiya T, Suhara T, Sudo Y, Okubo Y, Nakayama K, Nankai M, Inoue M, Yasuno F, Takano A, Maeda J, Shibuya H. Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol Psychiatry. 2002;51(9):715–722. [PubMed: 11983185]
7.
Suehiro M, Scheffel U, Ravert HT, Dannals RF, Wagner HN. [11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. Life Sci. 1993;53(11):883–892. [PubMed: 8366755]
8.
Jarkas N, Votaw JR, Voll RJ, Williams L, Camp VM, Owens MJ, Purselle DC, Bremner JD, Kilts CD, Nemeroff CB, Goodman MM. Carbon-11 HOMADAM: a novel PET radiotracer for imaging serotonin transporters. Nucl Med Biol. 2005;32(3):211–224. [PubMed: 15820756]
9.
Huang Y, Hwang DR, Bae SA, Sudo Y, Guo N, Zhu Z, Narendran R, Laruelle M. A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). Nucl Med Biol. 2004;31(5):543–556. [PubMed: 15219271]
10.
Huang Y, Hwang DR, Zhu Z, Bae SA, Guo N, Sudo Y, Kegeles LS, Laruelle M. Synthesis and pharmacological characterization of a new PET ligand for the serotonin transporter: [11C]5-bromo-2-[2-(dimethylaminomethylphenylsulfanyl)]phenylamine ([11C]DAPA). Nucl Med Biol. 2002;29(7):741–751. [PubMed: 12381454]
11.
Laruelle M, Vanisberg MA, Maloteaux JM. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry. 1988;24(3):299–309. [PubMed: 2969755]
12.
Huang Y, Hwang DR, Narendran R, Sudo Y, Chatterjee R, Bae SA, Mawlawi O, Kegeles LS, Wilson AA, Kung HF, Laruelle M. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab. 2002;22(11):1377–1398. [PubMed: 12439295]